Gain Therapeutics, Inc. (GANX) has 6 SEC Form 4 insider filings on record in the last 90 days. Most recent filing: July 17, 2026.
| Date | Insider | Value | Shares | Stake | Pre-planned | Links |
|---|---|---|---|---|---|---|
| July 17, 2026 filed July 15, 2026 | Nicaise Claude Director | $0 | 25,000 | 0% | No | |
|
|
||||||
| July 17, 2026 filed July 15, 2026 | GOLDSTEIN DOV A MD Director | $0 | 25,000 | 0% | No | |
|
|
||||||
| July 17, 2026 filed July 15, 2026 | Islam Khalid Director | $0 | 25,000 | 0% | No | |
|
|
||||||
| July 17, 2026 filed July 15, 2026 | Riley Jeffrey Scott Director | $0 | 25,000 | 0% | No | |
|
|
||||||
| July 17, 2026 filed July 15, 2026 | Melincoff Gwen A Director | $0 | 25,000 | 0% | No | |
|
|
||||||
Showing the 5 most recent of 6 filings in the last 90 days.
Form 4 is the filing company officers, directors and 10% shareholders must submit to the SEC within two business days of trading their own company's stock. Open-market purchases generally carry more signal than sales, which are often scheduled in advance. More on how this works.
Real-time Telegram alerts the moment a Form 4 is filed. Filings shown here are delayed by 72 hours.
Start free